PFE
vs
S&P 500
Over the past 12 months, PFE has underperformed S&P 500, delivering a return of -2% compared to the S&P 500's 24% growth.
Stocks Performance
PFE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
IE |
E
|
Endo International PLC
LSE:0Y5F
|
Performance Gap
PFE vs S&P 500
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
IE |
E
|
Endo International PLC
LSE:0Y5F
|
Performance By Year
PFE vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
|
US |
Eli Lilly and Co
NYSE:LLY
|
||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
||
US |
Johnson & Johnson
NYSE:JNJ
|
||
US |
Merck & Co Inc
NYSE:MRK
|
||
CH |
Roche Holding AG
SIX:ROG
|
||
UK |
AstraZeneca PLC
LSE:AZN
|
||
CH |
Novartis AG
SIX:NOVN
|
||
IE |
E
|
Endo International PLC
LSE:0Y5F
|
Competitors Performance
Pfizer Inc vs Peers
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
US |
G
|
GE Vernova LLC
NYSE:GEV
|
|
NL |
N
|
Nepi Rockcastle NV
JSE:NRP
|
|
US |
Schlumberger NV
NYSE:SLB
|
||
US |
B
|
Baker Hughes Co
NASDAQ:BKR
|
|
ID |
Amman Mineral Internasional Tbk PT
IDX:AMMN
|
||
US |
R
|
Reddit Inc
NYSE:RDDT
|
|
CH |
G
|
Galderma Group AG
SIX:GALD
|
|
US |
Halliburton Co
NYSE:HAL
|
||
LU |
Tenaris SA
MIL:TEN
|
||
IN |
Jio Financial Services Ltd
NSE:JIOFIN
|
Pfizer Inc
Glance View
Pfizer Inc., a name synonymous with pharmaceutical innovation, embarked on its journey in 1849 when German immigrants Charles Pfizer and Charles Erhart founded the company in Brooklyn, New York. Over the decades, the modest chemical business transformed into a titan of the pharmaceutical industry, delivering breakthroughs that have shaped modern medicine. The company operates through its robust engine of research and development, continually investing billions into discovering and bringing to market medications that address unmet medical needs. Spanning therapeutic areas such as oncology, vaccines, rare diseases, and cardiovascular and metabolic health, Pfizer's strategic focus ensures a diverse product pipeline that aligns with global health trends and challenges. The company's revenue model is predominantly driven by the development, marketing, and sale of its pharmaceutical products. Blockbuster drugs like Lipitor and recently, the COVID-19 vaccine developed in collaboration with BioNTech, have contributed significantly to its earnings. Pfizer's ability to maintain a strong balance between branded pharmaceuticals and generics allows it to effectively cater to both emerging markets and developed economies, while its strategic partnerships and acquisitions further bolster its reach and capabilities. The synergy of science and business acumen at Pfizer has made it not only a hub of medical innovation but also a formidable enterprise in the competitive landscape of healthcare.